Foreword  by Gabra, Hani
 e j c  s u p p l e m e n t s  1 2  ( 2 0 1 4 )  1
The articles in this supplement are based on presentations 
given at a PharmaMar-sponsored satellite symposium held 
at the British Gynaecological Cancer Society annual scientiﬁ c 
meeting, in July 2014 in London. The articles comprise mainly 
reviews of published data. They include a review of the recent 
stratiﬁ cation of the recurrent ovarian cancer population (ROC) 
into different, identiﬁ able subgroups based on platinum-free 
interval (PFI). This stratiﬁ cation will help guide treatment 
sequencing management strategies for these different 
patient groups. The articles also include a discussion of PFI 
extension strategies through intercalation of a non-platinum 
combination, such as trabectedin plus pegylated liposomal 
doxorubicin (PLD), between platinum therapies, and the 
survival advantage this brings. Clinical data from the pivotal 
OVA-301 trial of the non-platinum combination trabectedin 
+ PLD is presented. The last article presents a case history 
of a UK patient where this sequencing approach has been 
successfully undertaken.
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